Decision IntelPfizer
Pfizer Torcetrapib Clinical Trial Failure
Estimated impact: $800M+ direct investment; $21B market cap loss
Pfizer invested $800M in torcetrapib, a cholesterol drug designed to raise HDL ("good cholesterol"). The Phase III trial was terminated early when it increased death rates by 60%. Pfizer had built an entire manufacturing facility before the trial completed, committing to production before efficacy was proven.
Decision context
Whether to invest in manufacturing capacity and commercial launch preparations before Phase III clinical trial results confirmed safety and efficacy.
What the company’s own filing already carried
Not our reading of a memo. Pfizer's own 10-K, filed 2005-02-28 (11 months before the 2006 decision), was read by the audit engine's deterministic structural layer: the same detectors that run on every audit, with no language model involved. Everything below is drawn from the company's own disclosure, before any knowledge of what followed, and never from the decision itself.
Survivable as structured: if the flagged risk fires, the deal has the exits, cushions, or staging to absorb the hit and continue.
The structural layer flagged no unabsorbed condition in this filing.
- This reads the company's own 10-K (filed 11 months before the decision), not the decision memo itself, so it can only understate what a full audit of the memo would surface.
- It reads the structure of the situation, not the trigger: whether a shock to the flagged conditions would be absorbed, never that a shock arrives.
- A reading of a dated filing, not a prediction: every condition can be checked against the company's own 10-K.
Decision anatomy
Red = risk factor present · Green = protective factor present
Biases present in the decision
★ Primary driver · Severity estimated from bias type and decision outcome
Toxic combinations
The curated library this case sits in
Across all 155 curated case studies in our library, by documented outcome:
The library is curated toward documented failures, so this split describes the library, not the base rate of deals. The case above is one row in it.
Lessons learned
- Optimism bias in drug development led Pfizer to build manufacturing before pivotal trial results — a classic premature commitment
- The HDL hypothesis (raising HDL is always beneficial) was never rigorously validated, yet became consensus through anchoring to epidemiological correlations
- Sunk cost in R&D made it harder to interpret ambiguous interim data objectively
Source: Barter et al., "Effects of Torcetrapib in Patients at High Risk for Coronary Events," NEJM (2007) (Academic Paper)
These patterns were flaggable in Pfizer's own record — before the outcome.
See the full reasoning audit we ran — no login, no card. Then run the same audit on a deal you have already closed.
Or leave your email, we'll run the audit on a deal of your choosing and send the readout within a business day.
Workflows that fire on decisions like Pfizer’s
The same Recognition-Rigor Framework that documents this case audits memos in the same shape — before the outcome forces the lesson.